亚太鼻腔喷雾剂市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太鼻腔喷雾剂市场 – 行业趋势及 2030 年预测

  • Pharmaceutical
  • Published Report
  • Apr 2023
  • Asia-Pacific
  • 350 页面
  • 桌子數: 110
  • 图号: 47

Asia Pacific Nasal Spray Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD MILLION
Diagram Market Size (Forecast Year)
USD 6,248.16
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>亚太鼻喷雾剂市场,按产品类型(减充血鼻喷雾剂、类固醇鼻喷雾剂、盐水溶液/盐水鼻喷雾剂等)、容器设计(泵瓶和加压罐)、剂型(多剂量、单位/单剂量和双剂量)、治疗类别(抗组胺药、鼻用类固醇、肥大细胞抑制剂和抗胆碱能药物)、应用(鼻塞、过敏性和非过敏性鼻炎、中枢神经系统疾病、疫苗接种等)、处方/可用性(非处方药和处方药)、最终用户(家庭护理环境、医院、诊所和社区医疗保健)划分 - 行业趋势和预测到 2030 年。

亚太鼻腔喷雾剂市场

亚太鼻腔喷雾剂市场分析与洞察

过敏性鼻炎是全球五亿多人的主要健康问题。全球近一半的患者会出现鼻塞、打鼾、鼻后滴漏、咳嗽、嗅觉减退、头痛等症状,持续数月或数年。这些症状还会影响患者的生活质量。

亚太鼻腔喷雾剂市场亚太鼻腔喷雾剂市场

鼻喷雾剂是一种广泛用于鼻腔给药的系统,用于治疗主要过敏问题,如鼻塞、感染、眼睛发痒或流泪、流鼻涕、胸闷、咳嗽、喘息、呼吸困难、浅呼吸等。其他一些疾病还包括鼻息肉、炎症性肠病、肾脏相关问题等。通过喷雾剂以剂型通过鼻腔给药是一种非侵入性技术,可使药物在患者体内快速起效。鼻喷雾剂是最具成本效益的药物之一,无需侵入,易于使用和自行给药,患者依从性高。因此,鼻腔给药是近年来流行的给药途径之一,具有强大的增长机会。

鼻腔喷雾剂在市场上有非处方药 (OTC) 或处方药两种形式,用于治疗鼻部疾病,如鼻部过敏、鼻塞或鼻塞、慢性鼻窦炎、过敏性鼻炎和其他与鼻子相关的问题。这些喷雾剂在市场上有泵装或罐装两种形式。

Data Bridge Market Research 分析称,到 2030 年,亚太地区鼻腔喷雾剂市场规模预计将达到 62.4816 亿美元,预测期内的复合年增长率为 7.1%。

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史性的一年

2021 (可定制为 2015-2020)

定量单位

收入(百万美元)、销量(单位)和定价(美元)

涵盖的领域

Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)

Countries Covered

China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific

Market Players Covered

EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others

Market Definition

Nasal sprays are devices that help in the delivery of the drug through the nose in the nasal cavity to treat allergies and other problems related to brain inflammation, diabetes, dental problems, and the central nervous system. Allergy is a condition in which the immune system of the body reacts abnormally to a foreign substance. Nasal spray drug products consist of therapeutically active ingredients or drug substances in the form of solution or suspension of excipients.

There are different types of nasal spray available in the market, such as decongestion nasal spray, saline nasal spray, and steroid nasal spray. Decongestants are devices with drugs for the treatment of nasal congestion and provide short-term relief from a blocked nose. The decongestion nasal spray consists of drugs that open up the airways of the nasal part and helps in the breathing process.

During the cold and dry winter season, saline nasal sprays are used to avoid problems related to a stuffy nose. These devices are used to treat sinusitis, nasal crusting, and thin secretions of liquid from the nose, which are formed due to bacterial infection and lead to the dryness of the nasal area. This device helps in cleaning the nasal passage and mucus present in that area due to cold.

Asia-Pacific Nasal Spray Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVER

  • Increase in Infection and Allergic Cases

Allergy is a condition that makes the immune system weaken, and the immune system reacts abnormally to a foreign substance. Allergies have many forms, such as Allergic Rhinitis (AR), and this affects nearly 40 to 50 million people in the U.S. Some allergies may interfere with day-to-day activities and the quality of life.

Due to the increase in population, urbanization, and industrialization has increased tremendously, which has led to a rise in allergen. This allergen is responsible for allergies or infectious diseases in many people.

Thus, the rise in the prevalence of allergic diseases such as AR has led to an increase in the demand for nasal sprays, which is expected to drive market growth in the coming years.

RESTRAINT

  • Adverse Effects of Using Nasal Sprays

Many people opt for nasal sprays in order to get relief from a runny and stuffy nose, but using a nasal spray for a longer period of time causes several side effects. Steroid nasal sprays, also called corticosteroid nasal sprays, are anti-inflammatory medicines that are sprayed into the nose. They can be used to treat a range of conditions, including hay fever, sinusitis, non-allergic rhinitis, and nasal polyps. Some steroid nasal sprays are available to buy from pharmacies and shops, while others are only available on prescription.

Using nasal sprays for a prolonged period of time can lead to bleeding from the nose and even headaches. Some may experience other side effects, such as addiction or even congestion.

If one is taking a high dose for a long time, there is also a small chance one could get some of the side effects of steroid tablets, such as increased appetite, mood changes, and difficulty sleeping.

Thus, the adverse effects of nasal sprays are expected to restrain the market growth.

OPPORTUNITY

  • Expanding Therapeutic Applications for Nasal Sprays

Intranasal administration provides various useful options for the local and systemic delivery of diverse therapeutic agents for the treatment of problems such as allergies, respiratory diseases, and many others.

A nasal spray is one of the recently developed products, such as OptiNose and ViaNase, that helps to enable the targeting of formulations to a specific area of the site in the nasal cavity in humans.

Nasal therapy has been known as a form of treatment in Indian medicine for decades. It is also called “NASAYA KARMA” in Ayurvedic systems in Indian medicine.

The nasal spray consists of one or more than one therapeutically active ingredients in the form of suspension or solution in a non-pressurized dispenser. The most common allergy is AR.

Apart from respiratory problems, there are other therapeutic areas such as orthopedic, renal, and many other areas, where the nasal spray is playing important role in treating and curing such problems. In the future, other treatments may be developed that can help in the treatment of other problems easily.

CHALLENGE

  • Regulatory Hurdles

Nasal drug delivery can be evaluated by many regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA). These agencies provide a set of guidelines and regulations for any product before it is launched in the market. They allow performing various in vitro test methods for determining the characterization of nasal drug products and that should come in an acceptable range as given by such regulatory bodies.

Nasal spray can be designed as per the dose requirement of drug substances for patients suffering from nasal or any other issues. Some aspects of nasal sprays may be exceptional in the case of formulation, manufacturing, container closure system, stability, controls of critical steps, intermediates, and drug products. These aspects should be measured carefully while developing a program of nasal spray. Because of these changes ability of the product to treat patients may get affected.

Strict rules and regulations for the product for nasal spray manufacturing are more challenging for the manufacturer to get approval from regulatory agencies. The spray characteristics can be influenced by the design of the device, and by the handling of the device. Performing such tests to get the perfect result, that is, an acceptable range as given by the regulatory body, is more challenging in nasal spray manufacturing.

Post-COVID-19 Impact Analysis on the Asia-Pacific Nasal Spray Market

COVID-19 had a significant impact on the generic drug market for inhalation and nasal spray, as one of the main symptoms associated with COVID-19 is shortness of breath. The demand for inhalation and nasal spray increased during the pandemic.

For instance,

  • According to a MedComm journal article published in 2021, nasal sprays demonstrated the ability to be an effective COVID-19 treatment and vaccine option

Spray formulations that may inactivate SARS-CoV-2 or restrict its entry into cells were thought to be beneficial in preventing viral spread to the lungs or surrounding people. Relaxed lockdowns and the resumption of healthcare practices are expected to accelerate market growth in the post-pandemic era. COVID-19 patients are still experiencing long-term side effects such as shortness of breath.

Recent Developments

  • In January 2023, Viatris Inc. (NASDAQ: VTRS), a Asia-Pacific healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. This acquisition would help the company in its business expansion.
  • In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, announced the launch of additional strengths for the generic version of Revlimid1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S. This product launch would help the company in its product portfolio expansion.

Asia-Pacific Nasal Spray Market Scope

The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

  • DECONGESTION NASAL SPRAY
  • STEROID NASAL SPRAY
  • SALT WATER SOLUTION/ SALINE NASAL SPRAY
  • OTHERS

On the basis of product type, the market is segmented into decongestion nasal spray, salt water solution/saline nasal spray, steroid nasal spray, and others.

CONTAINER DESIGN

  • PUMP BOTTLES
  • PRESSURIZED CANISTERS

On the basis of container design, the market is segmented into pressurized canisters and pump bottles.

DOSAGE FORM

  • MULTI DOSE
  • UNIT/SINGLE DOSE
  • BI DOSE

On the basis of dosage form, the market is segmented into unit/single dose, bi dose, and multi dose.

THERAPEUTIC CLASS

  • ANTIHISTAMINE
  • NASAL STEROIDS
  • MAST CELL INHIBITOR
  • ANTICHOLINERGIC

On the basis of therapeutic class, the market is segmented into antihistamine, nasal steroids, mast cell inhibitor, and anticholinergic.

APPLICATION

  • NASAL CONGESTION
  • ALLERGIC AND NON-ALLERGIC RHINITIS
  • CENTRAL NERVOUS SYSTEM DISORDERS
  • VACCINATION
  • OTHERS

On the basis of application, the market is segmented into nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and others.

PRESCRIPTION/AVAILABILITY

  • OVER THE COUNTER
  • PRESCRIBED

On the basis of prescription/availability, the market is segmented into over the counter and prescribed.

END USER

  • HOME CARE SETTINGS
  • HOSPITALS
  • CLINICS
  • COMMUNITY HEALTH CARE

On the basis of end user, the market is segmented into home care settings, hospitals, clinics, and community health care.

鼻腔喷雾剂市场

Asia-Pacific Nasal Spray Market Regional Analysis/Insights

The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user.

The countries covered in this market report are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and the rest of Asia-Pacific.

In 2023, China is dominating the Asia-Pacific nasal spray market due to increasing customer inclinations toward nasal spray.

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了亚太品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战,以及销售渠道的影响。

竞争格局和亚太鼻腔喷雾剂市场份额分析

亚太鼻喷雾剂市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。

亚太地区鼻腔喷雾剂市场的一些主要市场参与者包括 EMERGENT、Cipla Inc.、Sandoz International GmbH(诺华旗下子公司)、Aytu Health(Aytu BioPharma, Inc. 的子公司)、Bayer AG、GlaxoSmithKline plc.、Assertio Therapeutics, Inc.、Aurena Laboratories.、J Pharmaceuticals、St. Renatus.、Ultratech India Limited、Catalent, Inc.、Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd 的子公司)、Pfizer Inc.、Viatris Inc.、LEEFORD HEALTHCARE LTD 和 Aishwarya Group 等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES MODEL

4.2 PESTEL ANALYSIS

5 INDUSTRY INSIGHTS: ASIA PACIFIC NASAL SPRAY MARKET

5.1 INDUSTRY INSIGHTS

6 REGULATIONS: ASIA PACIFIC NASAL SPRAY MARKET

6.1 REGULATORY SCENARIO IN INDIA

6.2 REGULATORY SCENARIO IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES

7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA

7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY

7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY

7.2 RESTRAINTS

7.2.1 PRODUCT RECALLS

7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS

7.3 OPPORTUNITIES

7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY

7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS

7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 REGULATORY HURDLES

7.4.2 ADDICTION TO NASAL SPRAY

8 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 DECONGESTION NASAL SPRAY

8.3 STEROID NASAL SPRAY

8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY

8.5 OTHERS

9 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN

9.1 OVERVIEW

9.2 PUMP BOTTLES

9.3 PRESSURIZED CANISTERS

10 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 MULTI DOSE

10.3 UNIT/SINGLE DOSE

10.4 BI DOSE

11 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS

11.1 OVERVIEW

11.2 ANTIHISTAMINE

11.3 NASAL STEROIDS

11.4 MAST CELL INHIBITOR

11.5 ANTICHOLINERGIC

12 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 NASAL CONGESTION

12.3 ALLERGIC AND NON-ALLERGIC RHINITIS

12.4 CENTRAL NERVOUS SYSTEM DISORDERS

12.5 VACCINATION

12.6 OTHERS

13 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY

13.1 OVERVIEW

13.2 PRESCRIBED

13.3 OVER THE COUNTER

14 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOME CARE SETTINGS

14.3 HOSPITALS

14.4 CLINICS

14.5 COMMUNITY HEALTH CARE

15 ASIA PACIFIC NASAL SPRAY MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 CHINA

15.1.2 JAPAN

15.1.3 INDIA

15.1.4 AUSTRALIA

15.1.5 SOUTH KOREA

15.1.6 MALAYSIA

15.1.7 THAILAND

15.1.8 SINGAPORE

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 REST OF ASIA-PACIFIC

16 ASIA PACIFIC NASAL SPRAY MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 GLAXOSMITHKLINE PLC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 EMERGENT

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 CATALENT, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.)

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 AISHWARYA GROUP

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 ASSERTIO THERAPEUTICS, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENT

18.9 AURENA LABORATORIES.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 BAYER AG

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 COMPANY SHARE ANALYSIS

18.10.4 PRODUCT PORTFOLIO

18.10.5 RECENT DEVELOPMENTS

18.11 CIPLA INC.

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 J PHARMACEUTICALS.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENTS

18.13 LEEFORD HEALTHCARE LTD

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

18.14 ST. RENATUS.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENTS

18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENTS

18.16 ULTRATECH INDIA LIMITED

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENTS

18.17 VIATRIS INC.

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 COMPANY SHARE ANALYSIS

18.17.4 PRODUCT PORTFOLIO

18.17.5 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表格列表

TABLE 1 ASIA PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 ASIA PACIFIC DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 ASIA PACIFIC STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 ASIA PACIFIC SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 5 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 ASIA PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 7 ASIA PACIFIC PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 ASIA PACIFIC PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 10 ASIA PACIFIC MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 ASIA PACIFIC UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 ASIA PACIFIC BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 13 ASIA PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 14 ASIA PACIFIC ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA PACIFIC NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA PACIFIC MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA PACIFIC ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 19 ASIA PACIFIC NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 ASIA PACIFIC ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA PACIFIC CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA PACIFIC VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA PACIFIC OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 25 ASIA PACIFIC PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA PACIFIC OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 ASIA PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 28 ASIA PACIFIC HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 ASIA PACIFIC HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA PACIFIC CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 ASIA PACIFIC COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 40 CHINA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 CHINA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 42 CHINA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 43 CHINA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 44 CHINA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 45 CHINA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 46 CHINA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 47 JAPAN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 JAPAN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 49 JAPAN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 50 JAPAN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 51 JAPAN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 52 JAPAN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 53 JAPAN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 54 INDIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 INDIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 56 INDIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 57 INDIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 58 INDIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 59 INDIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 60 INDIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 61 AUSTRALIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 62 AUSTRALIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 63 AUSTRALIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 64 AUSTRALIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 65 AUSTRALIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 66 AUSTRALIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 67 AUSTRALIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 SOUTH KOREA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 69 SOUTH KOREA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 70 SOUTH KOREA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 71 SOUTH KOREA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 72 SOUTH KOREA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 73 SOUTH KOREA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 74 SOUTH KOREA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 75 MALAYSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 MALAYSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 77 MALAYSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 78 MALAYSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 79 MALAYSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 MALAYSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 81 MALAYSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 THAILAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 83 THAILAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 84 THAILAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 85 THAILAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 86 THAILAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 87 THAILAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 88 THAILAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 89 SINGAPORE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 SINGAPORE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 91 SINGAPORE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 92 SINGAPORE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 93 SINGAPORE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 94 SINGAPORE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 95 SINGAPORE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 96 INDONESIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 INDONESIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 98 INDONESIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 99 INDONESIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 100 INDONESIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 INDONESIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 102 INDONESIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 PHILIPPINES NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 104 PHILIPPINES NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION)

TABLE 105 PHILIPPINES NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION)

TABLE 106 PHILIPPINES NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 107 PHILIPPINES NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 PHILIPPINES NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION)

TABLE 109 PHILIPPINES NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 110 REST OF ASIA-PACIFIC NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

图片列表

FIGURE 1 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC NASAL SPRAY MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC NASAL SPRAY MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC NASAL SPRAY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC NASAL SPRAY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC NASAL SPRAY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC NASAL SPRAY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA PACIFIC NASAL SPRAY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC NASAL SPRAY MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN INFECTION AND ALLERGIC CASES IS EXPECTED TO DRIVE THE ASIA PACIFIC NASAL SPRAY MARKET IN THE FORECAST PERIOD

FIGURE 12 THE DECONGESTION NASAL SPRAY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC NASAL SPRAY MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC NASAL SPRAY MARKET

FIGURE 14 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA PACIFIC NASAL SPRAY MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2022

FIGURE 19 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, 2023-2030 (USD MILLION)

FIGURE 20 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, CAGR (2023-2030)

FIGURE 21 ASIA PACIFIC NASAL SPRAY MARKET: BY CONTAINER DESIGN, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2022

FIGURE 23 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, 2023-2030 (USD MILLION)

FIGURE 24 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, CAGR (2023-2030)

FIGURE 25 ASIA PACIFIC NASAL SPRAY MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2022

FIGURE 27 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)

FIGURE 28 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)

FIGURE 29 ASIA PACIFIC NASAL SPRAY MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2022

FIGURE 31 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 32 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 33 ASIA PACIFIC NASAL SPRAY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2022

FIGURE 35 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, 2023-2030 (USD MILLION)

FIGURE 36 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, CAGR (2023-2030)

FIGURE 37 ASIA PACIFIC NASAL SPRAY MARKET: BY PRESCRIPTION/AVAILABILITY, LIFELINE CURVE

FIGURE 38 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2022

FIGURE 39 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 40 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 41 ASIA PACIFIC NASAL SPRAY MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC NASAL SPRAY MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022)

FIGURE 44 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 45 ASIA-PACIFIC NASAL SPRAY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 46 ASIA-PACIFIC NASAL SPRAY MARKET: PRODUCT TYPE (2023-2030)

FIGURE 47 ASIA PACIFIC NASAL SPRAY MARKET: COMPANY SHARE 2022 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Nasal Spray Market is projected to grow at a CAGR of 7.1% during the forecast period by 2030.
The future market value of the Asia-Pacific Nasal Spray Market is expected to reach USD 6,248.16 million by 2030.
The major players in the Asia-Pacific Nasal Spray Market are EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., etc.
The countries covered in the Asia-Pacific Nasal Spray Market are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific.